This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
SUPS 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
CUOS 2019
CUOS 2019 Bladder Cancer
CUOS 2019
Prostate Cancer
Bladder Cancer
Kidney Cancer
CUOS 2019 Bladder Cancer
Viewing 101-120 of 11531 articles
ASCO 2024: Avelumab First Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Histological Subtypes
ASCO 2024: Prognostic Impact of Residual Cancer Burden on Long-Term Outcomes After Neoadjuvant Androgen Receptor Pathway Inhibitor and Radical Prostatectomy for High-Risk Localized Prostate Cancer: A Pooled Analysis of Phase 2 Trials
ASCO 2024: Patient-Centered Approaches to Improve Quality of Life and Mitigate the Adverse Effects of Androgen Deprivation Therapy
ASCO 2024: Debunking the Frailty-Sarcopenia-ADT Axis in Metastatic Prostate Cancer with Multicomponent Exercise: The FIERCE Trial
ASCO 2024: A Phase II Trial of Enzalutamide with 5-Alpha Reductase Inhibitors as an ADT–Sparing Approach for Older Men with CSPC
ASCO 2024: Bone Resorptive Agents and Their Appropriate Use and Timing
ASCO 2024: Impact of Alterations in Tumor Suppressor Genes on Survival Outcomes in Patients with De Novo mCSPC Cancer Receiving ADT with ARPI or Docetaxel
ASCO 2024: Discussion: The Needle in the Haystack: Finding Biomarkers in Kidney Cancer
ASCO 2024: Discussion: Tailoring Treatment and Navigating Patient Preferences
ASCO 2024: ADT Sparing Approaches in the Metastatic Hormone-Sensitive and Castrate-Resistant Spaces
ASCO 2024: ARV-766, a PROTAC Androgen Receptor Degrader, in mCRPC: Initial Results of a Phase 1/2 Study
ASCO 2024: Prognostic PSMA-PET PROMISE Nomograms for Patients with Prostate Cancer
ASCO 2024: A Phase 1 Study of JNJ-69086420 (JNJ-6420), an Actinium-225 (225Ac)-Labeled Antibody Targeting Human Kallikrein 2, for mCRPC
ASCO 2024: Clinical Utility of Transcriptomic Signatures to Identify Androgen Receptor and Neuroendocrine Signaling in Prostate Cancer
ASCO 2024: Blood-Based Markers of Differential Efficacy of Bipolar Androgen Therapy and Enzalutamide in the Randomized TRANSFORMER Trial
ASCO 2024: DeLLpro-300: Phase 1b Study of Tarlatamab in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer
ASCO 2024: Nivolumab and Ipilimumab for Metastatic Prostate Cancer with an Immunogenic Signature: The NEPTUNES Multi-Centre Two-Cohort, Biomarker-Selected Phase 2 Trial
ASCO 2024: Oncogenic Alteration Rates, Race, and Prostate Cancer Specific Mortality in Veterans with Metastatic Prostate Cancer Undergoing Somatic Tumor next Generation Sequencing
ASCO 2024: Biomarker Analyses in Patients with Advanced Renal Cell Carcinoma from the Phase 3 CLEAR Trial
ASCO 2024: HERCULES (LACOG 0218): A Phase II Trial of Pembrolizumab plus Platinum-Based Chemotherapy as First-Line Systemic Therapy in Advanced Penile Cancer
1
2
3
4
5
6
7
8
9
10
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free